



# FINANCIAL TEAR SHEET

## CORPORATE PROFILE

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

## STOCK INFORMATION

### CHRS (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	<b>\$15.65</b>
Change (%)	▼ 0.15 (0.95%)
Volume	1,117,877
52 Week Low	\$14.00
Market Cap	\$802,659,031
Rolling EPS	-2.91
PE Ratio	N/A
Shares Outstanding	51,288,117

Data as of 06/23/17 4:00 p.m. ET



## RECENT NEWS & UPCOMING EVENTS

06/12/17

[Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 \(Pegfilgrastim Biosimilar Candidate\)](#)

06/01/17

[Coherus BioSciences Management to Present at 36th NASDAQ OMX Investor Program](#)

05/16/17

[Coherus BioSciences Prevails in '135 IPR Decision](#)

There are currently no events scheduled.

## SEC FILINGS

<b>Filing Date</b>	<b>Form</b>
06/12/17	<u>8-K</u>
06/05/17	<u>4</u>
05/19/17	<u>4</u>
05/19/17	<u>4</u>

## CORPORATE GOVERNANCE

<u>Denny Lanfear</u>	President, CEO and Chairman
<u>Barbara Finck, M.D.</u>	Chief Medical Officer
<u>Alan Herman, Ph.D.</u>	Chief Scientific Officer
<u>Jean-Frederic Viret, Ph.D.</u>	Chief Financial Officer
<u>Peter Watler, Ph.D.</u>	Chief Technical Officer
<u>Vince Anicetti</u>	SVP, Global Quality
<u>Lisa M. Bell, Ph.D.</u>	SVP, Regulatory Affairs
<u>Michael Fleming</u>	SVP, Commercial Strategy
<u>Matthew R. Hooper</u>	SVP, General Counsel

Data provided by Nasdaq. Minimum 15 minutes delayed.